Skip to content
2000
Volume 7, Issue 1
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Amidst the COVID-19 pandemic, the rapid development of vaccines transformed immunization strategies. With 70.6% of the global population vaccinated with at least one dose and 13.53 billion doses administered worldwide, certain dermatological side effects like Pityriasis Rubra Pilaris (PRP) have been linked to the COVID-19 vaccination. This review aims to critically analyze the existing evidence on the correlation between COVID-19 vaccination and PRP, emphasizing its incidence and management strategies. A review of 62 articles was conducted, of which only 19 met the inclusion criteria. Out of these, 16 had complete information necessary for the review. The review identified 16 cases of PRP, predominantly in males (62.5%) with an average age of 59. A significant percentage (44%) of cases occurred approximately 12 days after the third dose (booster). Symptoms commonly included painful rashes, itching, and erythematous, reddish, scaly plaques. Treatments varied, with oral retinoids and monoclonal antibody-based biological therapies being the most common. The importance of continuous monitoring of dermatological side effects, such as PRP, is underscored, especially as the world population will require ongoing booster shots. Standardizing PRP treatment is a critical step toward ensuring optimal patient care.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975311451240913043559
2024-09-24
2026-01-02

  • From This Site

    /content/journals/covid/10.2174/0126667975311451240913043559
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Pharmacovigilance and COVID-19. Vaccines - PAHO/WHO.2023Available from: https://www.paho.org/es/temas/servicios-salud/farmacovigilancia-covid-19-vacunas
  2. Pharmacovigilance - PAHO/WHO | Pan American Health Organization.2023Available from: https://www.paho.org/es/temas/farmacovigilancia
  3. World Health Organization. Vaccines and immunization.2023Available from: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1
  4. Coronavirus (COVID-19) vaccinations.2020Available from: https://ourworldindata.org/covid-vaccinations
  5. SpencerJ.P. PawlowskiT.R.H. ThomasS. Vaccine adverse events: Separating myth from reality.Am. Fam. Physician2017951278679428671426
     [Google Scholar]
  6. WangC.S. ChenH.H. LiuS.H. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review.J. Formos. Med. Assoc.202212151003100710.1016/j.jfma.2021.12.02835012825
     [Google Scholar]
  7. Health and Human Services. Vaccine side effects.2021Available from: https://www.hhs.gov/immunization/basics/safety/side-effects/index.html
  8. LladóI. ButrónB. Sampedro-RuizR. FragaJ. De ArgilaD. Pityriasis rubra pilaris after Vaxzevria® COVID-19 vaccine.J. Eur. Acad. Dermatol. Venereol.20213512e833e83510.1111/jdv.17542
     [Google Scholar]
  9. LeerunyakulK. PakornphadungsitK. SuchonwanitP. Case report: Pityriasis rosea-like eruption following covid-19 vaccination.Front. Med.2021810.3389/fmed.2021.752443
     [Google Scholar]
  10. BramhoffA.C. WesselmannU. BenderS.T. BerghoffA.V. HofmannS.C. BalakirskiG. Pityriasis rubra pilaris after COVID-19 vaccination: Causal relationship or coincidence?Dermatologie (Heidelb)202273863463710.1007/s00105‑022‑04972‑z35296923
     [Google Scholar]
  11. De CastroB.A.C. PereiraJ.M.M. MeyerR.L.B. Pityriasis lichenoides et varioliformis acuta after influenza vaccine.An. Bras. Dermatol.2015903)(Suppl. 1181184
     [Google Scholar]
  12. HunjanM.K. RobertsC. KarimS. HagueJ. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer–BioNTech) mRNA COVID-19 vaccine.Clin. Exp. Dermatol.202247118819010.1111/ced.1487834379821
     [Google Scholar]
  13. OrtizA.M. BernedoP.I. CasasA.H. YchasoG. Pityriasis rubra pilaris: About a case.Rev. Argent. Dermatol.202010132130
     [Google Scholar]
  14. LiuY. WangS. Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination.Skin Health Dis.202331e13910.1002/ski2.13935941937
     [Google Scholar]
  15. AjeboE.M. HowardJ.D. AnandD. DavisL.S. Pityriasis rubra pilaris potentially triggered by messenger RNA–1273 COVID vaccine.JAAD Case Rep.20222311411610.1016/j.jdcr.2022.03.01335465138
     [Google Scholar]
  16. WangD. ChongV.C.L. ChongW.S. OonH.H. A review on pityriasis rubra pilaris.Am. J. Clin. Dermatol.201819337739010.1007/s40257‑017‑0338‑129302927
     [Google Scholar]
  17. MorettaG. De LucaE.V. Di StefaniA. Management of refractory pityriasis rubra pilaris: Challenges and solutions.Clin. Cosmet. Investig. Dermatol.20171045145710.2147/CCID.S12435129184428
     [Google Scholar]
  18. SechiA. PierobonE. PezzoloE. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: Unravelling a possible common trigger, the COVID-19 vaccine.Clin. Exp. Dermatol.202247243744010.1111/ced.1497034617317
     [Google Scholar]
  19. CriadoP.R. IanhezM. RochaP.S. MiotH.A. Pityriasis rubra pilaris (type I) following ChAdOx1 COVID-19 vaccine: A report of two cases with successful treatment with oral isotretinoin.J. Eur. Acad. Dermatol. Venereol.2022367e508e51010.1111/jdv.1805535278239
     [Google Scholar]
  20. WadaM. LeeS. CurnowP. SimpsonI. MarA. A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine.JAAD Case Rep.202224747710.1016/j.jdcr.2022.04.02035529074
     [Google Scholar]
  21. GambichlerT. ScheelC.H. ArafatY. First onset of pityriasis rubra pilaris following SARS-CoV-2 booster vaccination: Case report and review of the literature.Dermato202223737810.3390/dermato2030008
     [Google Scholar]
  22. HlacaN. ZagarT. KastelanM. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer–BioNTech) COVID-19 vaccine.Dermatol. Ther.20223511e1579110.1111/dth.15791
     [Google Scholar]
  23. GamonalS.B.L. MarquesN.C.V. PereiraH.M.B. GamonalA.C.C. Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin.Dermatol. Ther.20223512e1589910.1111/dth.15899
     [Google Scholar]
  24. ZhaoP. RusuC.A. SchenckO.L. Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab.JAAD Case Rep.202335525610.1016/j.jdcr.2023.03.00337034027
     [Google Scholar]
  25. KondoS. OguraY. OhtsukaM. TokuraY. Pityriasis rubra pilaris following administration of SARS-CoV-2 vaccine.J. Cutan. Immunol. Allergy202366234236
     [Google Scholar]
  26. SaadM. BoseR. Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab.JAAD Case Rep.20234271110.1016/j.jdcr.2023.09.02437961078
     [Google Scholar]
  27. MoolaS. MunnZ. TufanaruC. AromatarisE. SearsK. SfetcuR. CurrieM. LisyK. QureshiR. MattisP. MuP.F. Systematic reviews of etiology and risk (2020). JBI Manual for Evidence Synthesis. JBI.2024
     [Google Scholar]
  28. HeibelM.D. HeibelH.D. Successful treatment of type I pityriasis rubra pilaris with ixekizumab.JAAD Case Rep.20184877477610.1016/j.jdcr.2018.05.00630246123
     [Google Scholar]
  29. GauciM.L. JachietM. GottliebJ. Successful treatment of type II pityriasis rubra pilaris with secukinumab.JAAD Case Rep.20162646246410.1016/j.jdcr.2016.09.00627981219
     [Google Scholar]
  30. AlazemiA. BalakirskiG. AlShehhiF. LehmannS. TenbrockK. MegahedM. Juvenile pityriasis rubra pilaris: Successful treatment with methotrexate.Clin. Exp. Dermatol.201843111011210.1111/ced.1328129072324
     [Google Scholar]
  31. AroraA. MohtaA. GhiyaB.C. JangirK.V. Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: Decoding a possible trigger.J. Cosmet. Dermatol.20222183206320710.1111/jocd.1493335332643
     [Google Scholar]
  32. DoğanY. Pityriasis rubra pilaris type IV-associated arthritis treated with adalimumab.Int. J. Rheum. Dis.20232661157116110.1111/1756‑185X.1459736722459
     [Google Scholar]
  33. LiangJ. YeR. TianX. ZhangS. ZhangX. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.Dermatol. Ther.2020336e1409710.1111/dth.1409732725719
     [Google Scholar]
  34. MirallesE.S. NúñezM. De Las HerasM.E. PérezB. MorenoR. LedoA. Pityriasis rubra pilaris and human immunodeficiency virus infection.Br. J. Dermatol.1995133699099310.1111/j.1365‑2133.1995.tb06939.x
     [Google Scholar]
  35. González-LópezA. VelascoE. PozoT. Del VillarA. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy.Br. J. Dermatol.1999140593193410.1046/j.1365‑2133.1999.02829.x
     [Google Scholar]
  36. MartinA.G. WeaverC.C. CockerellC.J. BergerT.G. Pityriasis rubra pilaris in the setting of HIV infection: Clinical behaviour and association with explosive cystic acne.Br. J. Dermatol.1992126661762010.1111/j.1365‑2133.1992.tb00111.x1535216
     [Google Scholar]
  37. DurieuxN. VandenputS. PasleauF. [OCEBM levels of evidence system]Rev. Med. Liege20136812644649[OCEBM levels of evidence system24564030
     [Google Scholar]
  38. KromerC. SabatR. CelisD. MössnerR. Systemic therapies of pityriasis rubra pilaris: A systematic review.J. Dtsch. Dermatol. Ges.201917324325910.1111/ddg.1371830520557
     [Google Scholar]
/content/journals/covid/10.2174/0126667975311451240913043559
Loading
COVID-19 Vaccination-induced Pityriasis Rubra Pilaris
Coronaviruses 7, E26667975311451 (2026); https://doi.org/10.2174/0126667975311451240913043559
/content/journals/covid/10.2174/0126667975311451240913043559
/content/journals/covid/10.2174/0126667975311451240913043559
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): COVID-19; dermatology; drug monitoring; pityriasis; pityriasis rubra pilaris (PRP); vaccination

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test